Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (3): 489-491    DOI: 10.31083/j.ejgo.2020.03.5288
Case Report Previous articles | Next articles
Neoadjuvant chemotherapy followed by radical surgery for Stage IB2 cervical cancer in pregnancy
X.F. Xu1, Q. Li1, A.Y. Dai1, H.J. Zhou1, J.X. Ling1()
1Department of Obstetrics and Gynecology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, 210008, China
Download:  PDF(524KB)  ( 213 ) Full text   ( 10 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Background: Pregnancy with cervical cancer (CC) represents an important challenge. Case Report: The authors report a case of a 34-year old diagnosed with Stage IB2 squamous cell cervical cancer at 24+-week gestation who was then treated with neoadjuvant chemotherapy followed by cesarean section and radical hysterectomy with good outcome of both the mother and the baby. Conclusion: The results of this case study, combined with previous reports and the authors’ clincal experience, support the combination of paclitaxel and cisplatin for neoadjuvant chemotherapy when treating FIGO Stage IB2 cervical cancer in pregnancy.

Key words:  Cancer      Carcinoma      Chemotherapy      Gynecological cancers      Mid-trimester pregnancy     
Submitted:  17 June 2019      Accepted:  08 August 2019      Published:  15 June 2020     
*Corresponding Author(s):  J.X. Ling     E-mail:  lingjingxiangy@163.com

Cite this article: 

X.F. Xu, Q. Li, A.Y. Dai, H.J. Zhou, J.X. Ling. Neoadjuvant chemotherapy followed by radical surgery for Stage IB2 cervical cancer in pregnancy. European Journal of Gynaecological Oncology, 2020, 41(3): 489-491.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.03.5288     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I3/489

Figure 1.  — Surgical specimen of uterus. The patient diagnosed with IB2 CC in midtrimester pregnancy received neoadjuvant chemotherapy followed caesarean section and radical surgery.

[1] Eibye S., Kjaer S.K., Mellemkjaer L.: “Incidence of pregnancy-associated cancer in Denmark, 1977-2006”. Obstet. Gynecol., 2013, 122, 608.
doi: 10.1097/AOG.0b013e3182a057a2
[2] Bigelow C.A., Horowitz N.S., Goodman A., Growdon W.B., Del Carmen M., Kaimal A.J.: “Management and outcome of cervical cancer diagnosed in pregnancy”. Am. J. Obstet. Gynecol., 2017, 216, 276.
doi: 10.1016/j.ajog.2016.10.034 pmid: 27810552
[3] Islam S., Mukhopadhyay L., Howells R.: “Neo-adjuvant chemotherapy and radical surgery for stage 1B cervical cancer in pregnancy”. J. Obstet. Gynaecol., 2012, 32, 191.
doi: 10.3109/01443615.2011.645094 pmid: 22296440
[4] Dawood R., Instone M., Kehoe S.: “Neo-adjuvant chemotherapy for cervical cancer in pregnancy: a case report and literature review”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2013, 171, 205.
doi: 10.1016/j.ejogrb.2013.09.008 pmid: 24139541
[5] Li J., Wang L., Zhang B., Peng Y., Lin Z.: “Neoadjuvant chemotherapy with paclitaxel plus platinum for invasive cervical cancer in pregnancy: two case report and literature review”. Arch. Gynecol. Obstet., 2011, 284, 779.
doi: 10.1007/s00404-011-1943-5
[6] Marnitz S., Köhler C., Oppelt P., Schmittel A., Favero G., Hasenbein K., et al.: “Cisplatin application in pregnancy: first in vivo analysis of 7 patients”. Oncology, 2010, 79, 72.
doi: 10.1159/000320156 pmid: 21071993
[7] Zagouri F., Sergentanis T.N., Chrysikos D., Bartsch R.: “Platinum derivatives during pregnancy in cervical cancer: a systematic review and metaanalysis”. Obstet. Gynecol., 2013, 121, 337.
doi: 10.1097/AOG.0b013e31827c5822
[8] Zagouri F., Dimitrakakis C., Marinopoulos S., Tsigginou A., Dimopoulos M.A.: “Cancer in pregnancy: disentangling treatment modalities”. ESMO Open, 2016, 1, e000016.
doi: 10.1136/esmoopen-2015-000016 pmid: 27843602
[9] Azim H.A. Jr., Peccatori F.A., Pavlidis N.: “Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors”. Cancer Treat. Rev., 2010, 36, 101.
doi: 10.1016/j.ctrv.2009.11.007 pmid: 20015593
[10] Van Calsteren K., Verbesselt R., Ottevanger N., Halaska M., Heyns L., Van Bree R., et al.: “Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study”. Acta Obstet. Gynecol. Scand., 2010, 89, 1338.
doi: 10.3109/00016349.2010.512070 pmid: 20846067
[1] Ikuji Shimazaki, Yasunori Hashiguchi, Makoto Yamauchi, Mari Kasai, Takeshi Fukuda, Tomoyuki Ichimura, Tomoyo Yasui, Toshiyuki Sumi. Secondary small cell vaginal cancer after operative therapy for endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 821-823.
[2] Polyana Barbosa Silva, Millena Prata Jammal, Márcia Antoniazi Michelin, Eddie Fernando Cândido Murta. Phenotypic differences of tecidual TDCs obtained from breast cancer mice[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 689-698.
[3] Yu Hui Lim, Sheow Lei Lim, Linda Xiao Hui Lin, Lay Tin Soh, Hoon Seng Khoo Tan, Richard Ming Chert Yeo, Timothy Yong Kuei Lim. Sequential Chemoradiation versus Radiation for the Adjuvant Treatment of Stage III Endometrioid Adenocarcinoma of the Uterus[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 705-712.
[4] Eda Kucuktulu, Ahmet Fatih Yurekli. Simultaneous Integrated Intensity Modulated Radiotherapy Boost for Gynecological Cancer when Brachytherapy is not an Option[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 720-725.
[5] Buse Güler, Merve Çamlıbel, Samiye Mete. What Do Relatives of Turkish Women with Ovarian Cancer Share on Websites? : A Qualitative Research[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 732-738.
[6] Huifen Zhen, Fan Guo, Xiaojun Zhang, Miaomiao Jia, Haibo Yang, Yarong Yao, Yuandong Li, Jinnan Gao. The effects of chemotherapy with anthracyclines vs capecitabine on tumour size, survival rate and estradiol levels in patients with locally advanced breast cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 785-789.
[7] Youngsun Kim, Sungkyoung Moon, Kiyong Na. Metastatic mesonephric adenocarcinoma of unknown origin after hysterectomy: A case report[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 828-832.
[8] Wook Youn Kim, Shin Hee Seo, Seung-Hyuk Shim, Jin Hee Park, Hyung Kyu Park, Kyeong A So, Tae Jin Kim, Sun Joo Lee. Correlation of immunohistochemistry and silver in situ hybridization for the assessment of c-MET in uterine cervical cancer patients treated with radical hysterectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 745-752.
[9] Katselashvili Lika, Jokhadze Natia, Katcharava Margarita, Vardiashvili Nino. Breast Cancer Metastatic to Vulva - a Case Report[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 845-848.
[10] Yanan Li, Dongge Wang, Xiaodong Li, Wangchao Zhang, Xianghua Huang, Yibin Liu. Appendix invasion of squamous cell carcinoma arising from ovarian mature cystic teratoma and resistant to combination chemotherapy with docetaxel and oxaliplatin: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 841-844.
[11] John P. Micha, Howard D. Epstein, Michael C. Roossin, Randy Bohart, Mark A. Rettenmaier, Bram H. Goldstein. Neoadjuvant chemotherapy, radical hysterectomy and chemoradiation for stage iva cervical carcinoma[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 797-801.
[12] Yudi Mulyana Hidayat, Gatot Nyarumenteng Adhipurnawan Winarno, Maringan Diapari Lumban Tobing, Arieff Kustiandi, Kemala Isnainiasih Mantilidewi, Sofie Rifayani Krisnadi. The Role of Akt2 and CA-125 Serum Levels as Predictors for Successful Cytoreduction in Epithelial Ovarian Cancer Surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 739-744.
[13] Juan Xu, Qingqing Tan, Ting Li. USP22 promotes the expression of GLUT1 and HK2 to facilitate growth and glycolysis in cervical cancer cells[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 790-796.
[14] Qianqian Tang, Shi Wan, Xiaogai Qiao, Fang Wang, Yan Wang. MiR-29 promotes ovarian carcinoma cell proliferation through the PTEN pathway[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 774-778.
[15] Lingyun Zhai, Lixin Zeng, Hongru Jiang, Wei Li. Effects of a cyclooxygenase-1-selective inhibitor in combination with taxol or cisplatin on cyclin D1, apoptosis, and vascular endothelial growth factor in a xenograft model of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 779-784.
No Suggested Reading articles found!